Inovio Stock Up, Zika Vaccine Gets Nod For Phase I Study
Zacks Investment Research | Jun 21, 2016 04:51AM ET
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and partner GeneOne Life Science, Inc. announced that they have gained approval for the initiation of a phase I study evaluating Zika vaccine, GLS-5700. Inovio’s shares jumped almost 7% following the announcement.
The open-label, dose-ranging study will involve 40 human volunteers and evaluate the safety, tolerability and immunogenicity of GLS-5700 administered intradermally using Inovio’s proprietary DNA delivery device Cellectra. While dosing is expected to begin over the coming weeks, interim results from the study are anticipated later this year.
Per Inovio’s press release, 58 countries and territories have reported continuing spread of this mosquito-borne virus as of May 2016. Moreover, the incidences of viral infection and medical conditions caused by this virus are increasing rather than diminishing.
Although Zika virus is generally associated with common symptoms like fever, rash, joint pain, and conjunctivitis, it can also lead to a severe birth defect called microcephaly which arises from infection during pregnancy. We note that the outbreak of Zika virus was declared a public health emergency of international concern by the World Health Organization earlier this year.
With no approved vaccine or treatment for this virulent virus, companies like Intrexon Corp. (NYSE:XON) among others are also looking to develop Zika vaccines.
Inovio is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Retrophin, Inc. (NASDAQ:RTRX) , each sporting a Zacks Rank #1 (Strong Buy).
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.